CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Phase 1 Terminated 9 enrolled Shanghai PerHum Therapeutics Co., Ltd. Shanghai Zhongshan Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This clinical study is to investigate the safety and tolerability of CCT301-38 CAR modified autologous T cells (CCT301-38) in subjects with relapsed or refractory AXL positive sarcomas

Timeline

Start: 2021-12-30
Primary completion: 2024-08-15
Completion: 2024-10-24

Outcome

Outcome not reported

Stopped (Business): “Adjustment of study strategy”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CCT301-38	Cell therapy	—	Intravenous

Indications

No indication recorded.